ORASIS IS DEVELOPING a corrective eye drop to treat presbyopia as an alternative to reading glasses. Presbyopia, the inability to focus on near objects, typically occurs after the age of 40 and affects more than 1.8 billion people worldwide.
Our product CSF-1 is an eye drop being developed to improve the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be not only effective, but also safe, comfortable, and easy-to-use.
Orasis is led by a collaborative team of industry executives and ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development
ORASIS IS FUNDED by a diverse group of sophisticated and experienced life science and healthcare investors including the ophthalmology focused venture capital fund Visionary Ventures, Sequioa Capital, SBI (Japan) Innovation Fund, LifeSci Venture Partners, Maverick Ventures Israel, and other private investors.
Orasis is based in Herzliya, Israel.